Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated reports developments for a global medical technology business that supplies hospitals and healthcare providers with devices used in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Its established brands include Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck.
Recurring Teleflex news covers quarterly financial results, outlook updates, revenue trends by global product category, portfolio realignment and integration of acquired vascular intervention assets. Company updates also include governance and leadership changes, board committee matters, capital allocation actions, shareholder communications and operational initiatives such as integrated demand and supply planning.
Teleflex (NYSE: TFX) has launched a national advertising campaign to promote the UroLift® System, an innovative, minimally invasive treatment for benign prostatic hyperplasia (BPH). This humorous campaign emphasizes the importance of health screenings for men and aims to encourage visits to urologists. BPH, which affects many aging men, can cause disruptive urinary symptoms. The UroLift® System has treated over 400,000 men globally, offering a solution without severe side effects like erectile dysfunction. The 5-year durability data shows a 2-3% surgical retreatment rate annually.
Teleflex, a global provider of medical technologies, announced that Liam Kelly, its Chairman, President, and CEO, will speak at the 41st Annual J.P. Morgan Healthcare Conference. The event is set for January 10, 2023, at 3:00 p.m. PT in San Francisco, California. A live audio webcast and presentation slides will be accessible on the Teleflex investor website. Teleflex focuses on innovative solutions in various medical fields, including vascular access and emergency medicine. More information can be found at teleflex.com.
Summary not available.
Liam Kelly, Chairman, President and CEO of Teleflex, will present at the 34th Annual Piper Sandler Healthcare Conference in New York on November 30, 2022, at 1:30 p.m. (ET). A live audio webcast of the presentation can be accessed via the investor section of the Teleflex website. Teleflex specializes in medical technologies that enhance health and quality of life, with innovative solutions in vascular access, interventional cardiology, anesthesia, and more. For additional details, visit teleflex.com.
Teleflex (NYSE: TFX) has announced a worldwide recall of specific lots of its Gibeck® Iso-Gard® Filters due to potential risks including splitting or detaching during use, which could compromise patient air supply. The recall, which affects products manufactured between December 17, 2019, and March 26, 2022, was expanded after 38 complaints were reported, including 4 injuries related to patient desaturation, but no deaths or long-term injuries. The FDA classified the recall as Class I, indicating serious health risks associated with the affected filters.
Teleflex, a global provider of medical technologies, announced that Liam Kelly, Chairman, President and CEO, will present at the Jefferies London Healthcare Conference on November 15, 2022, at 2:40 p.m. (GMT). A live audio webcast of the presentation will be accessible via the investor section of the Teleflex website. The company focuses on purpose-driven innovation to enhance healthcare, with a diverse portfolio that includes products for vascular access, interventional cardiology, and more. For more details, visit teleflex.com.
Teleflex announced a quarterly cash dividend of $0.34 per share, payable on December 15, 2022 to shareholders on record by November 15, 2022. This decision underscores the company’s commitment to shareholder returns while continuing its focus on providing medical technologies that enhance patient care.
Teleflex announced Q3 2022 financial results with revenues of $686.8 million, representing a 1.9% decline year-over-year, partially offset by a 2.4% increase in constant currency. GAAP diluted EPS dropped to $2.16 from $4.20 in the prior year. The company lowered its GAAP revenue growth guidance to (0.75)% to 0.25% and adjusted diluted EPS guidance to $12.80 to $13.20. The acquisition of Standard Bariatrics aligns with its M&A strategy, contributing to revenue and margin growth.
Teleflex (NYSE: TFX) announced results from a new study published in the Journal of Endourology demonstrating that the UroLift® System is effective for treating benign prostatic hyperplasia (BPH), specifically in patients with obstructive median lobes. Compared to TURP, patients treated with UroLift experienced significantly greater symptom improvement, faster satisfaction, and fewer post-op catheterizations. The analysis combined outcomes from controlled trials and real-world settings, confirming the safety and effectiveness of the UroLift System.
Teleflex (NYSE: TFX) will hold a conference call on October 27, 2022, at 8:00 a.m. ET to discuss its third-quarter financial results and operational updates. Participants can pre-register via the provided link or join via a live audio webcast on the company’s website. An audio replay will be accessible after 11:00 a.m. ET on the same day. Teleflex specializes in medical technologies that enhance health outcomes, with a diverse portfolio spanning vascular access, anesthesia, and surgical care.